A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 96
Summary
- Conditions
- Fallopian Tube Cancer
- Bladder Urothelial Carcinoma
- Breast Cancer
- Cholangiocarcinoma
- Esophageal Cancer
- Gastric Cancer
- Primary Peritoneal Carcinoma
- Head and Neck Cancer
- Renal Cell Carcinoma
- Hepatic Cancer
- MSI-H Colorectal Cancer
- Non -Small Cell Lung Cancer
- Ovarian Cancer
- Other Solid Tumors
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This study will determine the safety, tolerability and activity of CDX-527. Eligible patients that enroll to the dose-escalation portion of the study will be assigned to one of several dose levels of CDX-527. The dose-escalation part of the study will determine the safety profile of CDX-527 and dete...
This study will determine the safety, tolerability and activity of CDX-527. Eligible patients that enroll to the dose-escalation portion of the study will be assigned to one of several dose levels of CDX-527. The dose-escalation part of the study will determine the safety profile of CDX-527 and determine which dose(s) of CDX-527 will be studied in the expansion part of the study. The expansion part of the study will enroll eligible patients with certain solid tumors to be treated at dose(s) identified during dose-escalation Up to 40 patients will be enrolled. All patients enrolled in the study will be closely monitored to determine if there is a response to the treatment as well as for any side effects that may occur.
Tracking Information
- NCT #
- NCT04440943
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon